Recursion Pharmaceuticals Director Executes $105,600 Stock Sale Amid Mixed Q1 Results
Blake Borgeson, a director at Recursion Pharmaceuticals (NASDAQ:RXRX), has completed a sale of 30,000 shares of Class A Common Stock. The transaction, valued at $105,600, took place on May 5, 2026, with shares priced at $3.52 each. This divestment was conducted through a Rule 10b5-1 trading plan that Borgeson had established back on August 31, 2025…